{"company":{"id":3103116,"name":"Verastem Oncology","domain":"verastem.com","url":"https://alion.io/company/verastem"},"section":"news","answer":"Verastem Oncology: 8 headlines on record, 2 headlines in the last 90 days. Its story counts 4 milestones.","figures":[{"label":"Headlines","value":"8"},{"label":"In 90 days","value":"2"},{"label":"Milestones","value":"4"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":8},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":4}],"news":[{"date":"2026-09-24","kind":"News","title":"Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/verastem-oncology-announces-breaking-oral-123000320.html"},{"date":"2026-09-24","kind":"News","title":"Verastem data on ovarian cancer drug combo set for IGCS 2026","source":"streetinsider.com","url":"https://streetinsider.com/Corporate+News/Verastem+data+on+ovarian+cancer+drug+combo+set+for+IGCS+2026/27099336.html"},{"date":"2026-06-22","kind":"Press release","title":"Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program","source":"businesswire.com","url":"https://businesswire.com/news/home/20260615846661/en/Verastem-Oncology-to-Host-Investor-Conference-Call-and-Report-Updated-Data-and-Progress-Across-VS-7375-Oral-KRAS-G12D-ONOFF-Inhibitor-TARGET-D-Clinical-Program"},{"date":"2026-05-10","kind":"Press release","title":"Verastem Inc Earnings Call Highlights Growth And Risk","source":"The Globe and Mail","url":"https://theglobeandmail.com/investing/markets/stocks/VSTM/pressreleases/1833350/verastem-inc-earnings-call-highlights-growth-and-risk/"},{"date":"2026-04-20","kind":"News","title":"Vectoring In On Verastem","source":"seekingalpha.com","url":"https://seekingalpha.com/article/4891900-vectoring-in-on-verastem"},{"date":"2025-06-02","kind":"News","title":"What's Going On With Verastem Oncology Stock On Monday?","source":"benzinga.com","url":"https://benzinga.com/news/health-care/25/06/45728052/whats-going-on-with-verastem-oncology-stock-on-monday"},{"date":"2024-03-18","kind":"News","title":"Verastem, with FDA filing imminent, shows toll rare cancer takes on well-being","source":"fiercepharma.com","url":"https://fiercepharma.com/marketing/verastem-fda-filing-imminent-shows-toll-rare-cancer-takes-wellbeing"},{"date":"2022-10-20","kind":"Press release","title":"Verastem Oncology Appoints Anil Kapur to Board of Directors","source":"businesswire.com","url":"https://businesswire.com/news/home/20221020005188/en/Verastem-Oncology-Appoints-Anil-Kapur-to-Board-of-Directors"}],"story":[{"title":"Board appointment Verastem Oncology Appoints Anil Kapur to Board of Directors · businesswire.com","url":"https://businesswire.com/news/home/20221020005188/en/Verastem-Oncology-Appoints-Anil-Kapur-to-Board-of-Directors"},{"title":"Raised a round Venture round $100M · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/1526119/000090445420000278/"},{"title":"Raised a round Convertible Note $4.8M · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/1526119/000090445420000009/"},{"title":"Founded"}],"as_of":"2026-11-16","cite":"Verastem Oncology, News. Alion, Nov 16, 2026. https://alion.io/company/verastem/news","html_url":"https://alion.io/company/verastem/news","json_url":"https://alion.io/company/verastem/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-16T00:15:06Z"}}